(Q44282409)

English

Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin

scientific article published in January 2003

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Helicobacter pylori

1 reference

based on heuristic

inferred from title

eradication of infectious diseases

1 reference

based on heuristic

inferred from title

antibiotic resistance

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Helicobacter pylori infectious disease

1 reference

based on heuristic

inferred from title

author name string

H Kawabata

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Y Habu

2

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

H Tomioka

3

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

H Kutsumi

4

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

M Kobayashi

5

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

K Oyasu

6

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

T Hayakumo

7

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

S Mizuno

8

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

K Kiyota

9

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

M Nakajima

10

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

K Kimoto

11

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

H Inokuchi

12

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

K Kawai

13

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

language of work or name

0 references

publication date

1 January 2003

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

259-264

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Helicobacter pylori infection and the development of gastric cancer

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01406.X

21 January 2018

Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01406.X

21 January 2018

Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01406.X

21 January 2018

Interphenotype differences in disposition and effect on gastrin levels of omeprazole—suitability of omeprazole as a probe for CYP2C19

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01406.X

21 January 2018

Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01406.X

21 January 2018

Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01406.X

21 January 2018

Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01406.X

21 January 2018

Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01406.X

21 January 2018

PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORI

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01406.X

21 January 2018

Gastric Campylobacter-like organisms, gastritis, and peptic ulcer disease.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01406.X

21 January 2018

Healing gastric MALT lymphomas by eradicating H pylori?

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01406.X

21 January 2018

Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01406.X

21 January 2018

Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01406.X

21 January 2018

Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01406.X

21 January 2018

Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01406.X

21 January 2018

Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01406.X

21 January 2018

Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01406.X

21 January 2018

A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01406.X

21 January 2018

Specific proton pump inhibitors E3810 and lansoprazole affect the recovery process of gastric secretion in rats differently

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01406.X

21 January 2018

Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01406.X

21 January 2018

Triple therapy with omeprazole, amoxicillin and clarithromycin is effective against Helicobacter pylori infection in gastric ulcer patients as well as in duodenal ulcer patients. Results of a randomized controlled trial in Japan

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01406.X

21 January 2018

Identifiers

10.1046/J.1365-2036.2003.01406.X

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44282409&oldid=2109120052"